A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
PHA – June 2022
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
